Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026 US$ 29.70 ★★★★★ 4.6 (8 reviews)
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 US$ 26.75 ★★★★★ 4.6 (23 reviews)
Novo Nordisk has officially filed for FDA approval of CagriSema, a powerful new once-weekly injection that combines a GLP-1 receptor agonist with an amylin analogue, setting the stage for the next major US$ 27.41 ★★★★★ 5.0 (18 reviews)
Presenters to provide first look at data from REIMAGINE trials of cagrilintide/semaglutide for type 2 diabetes management US$ 24.82 ★★★★★ 4.8 (23 reviews)
Cagrilintide–semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study US$ 22.98 ★★★★★ 4.6 (16 reviews)
cagrilintide semaglutide combination cagrisema phase 3 results 2024 2025 What is the pipeline for future medications for obesity? US$ 25.71 ★★★★★ 4.0 (26 reviews)
Three new phase 3 REIMAGINE studies provide some of the strongest evidence yet for CagriSema® (cagrilintide + semaglutide) in type 2 diabetes. 🔹 REIMAGINE 1 Studied people with early type 2 diabetes US$ 21.24 ★★★★★ 4.6 (5 reviews)
Updates in Medicine | CagriSema in Adults With or Without Diabetes – REDEFINE 1 & 2 • 💊 Cagrilintide 2.4 mg + Semaglutide 2.4 mg once weekly • 📉 –20.4% weight US$ 28.78 ★★★★★ 4.1 (5 reviews)
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes US$ 23.94 ★★★★★ 4.4 (10 reviews)
cagrilintide semaglutide combination cagrisema phase 3 results 2024 2025 Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, US$ 20.41 ★★★★★ 4.8 (18 reviews)
Cagrilintide–semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study US$ 24.18 ★★★★★ 4.5 (24 reviews)
Presenters to provide first look at data from REIMAGINE trials of cagrilintide/semaglutide for type 2 diabetes management US$ 22.76 ★★★★★ 4.6 (11 reviews)
Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study US$ 26.77 ★★★★★ 4.1 (16 reviews)
Novo Nordisk has officially filed for FDA approval of CagriSema, a powerful new once-weekly injection that combines a GLP-1 receptor agonist with an amylin analogue, setting the stage for the next major US$ 23.86 ★★★★★ 4.7 (5 reviews)
Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints US$ 27.54 ★★★★★ 5.0 (11 reviews)
We are all anxiously awaiting more research on the combination of cagrilintide and semaglutide (#ozempic/#wegovy) which has been shown in global studies to induce very meaningful #weightloss. This study assessed the efficacy US$ 22.69 ★★★★★ 4.3 (9 reviews)
Novo Nordisk to present array of new portfolio data including studies with semaglutide and CagriSema, expanding evidence in obesity and diabetes care at ADA 2025 US$ 21.75 ★★★★★ 4.6 (22 reviews)
L-Carnitine (Mixed Fruit) – Outlastlabz US$ 25.34 Min. order: 1 piece ★★★★★ 4.4 (22 reviews) Sold : Login>>
How To Reconstitute KLOW Protocol Peptides US$ 22.55 Min. order: 1 piece ★★★★★ 4.3 (20 reviews) Sold : Login>>
CoolSculpting | Brazilian Body Contouring Knoxville US$ 25.06 Min. order: 1 piece ★★★★★ 4.5 (29 reviews) Sold : Login>>
Alpha Supps L-Carnitine 3000 Liquid — Stimulant-Free Amino Acid — Gummy Worms – 31 Serv US$ 27.69 Min. order: 1 piece ★★★★★ 4.0 (11 reviews) Sold : Login>>
RETREAT Aesthetic & Vitality Center | When weight changes, your shape changes too. GLP-1 medications can help patients lose overall body weight, improving metabolic health and US$ 23.98 Min. order: 1 piece ★★★★★ 4.8 (14 reviews) Sold : Login>>
